You are using an outdated browser. Please upgrade your browser to improve your experience.


a potassium-competitive proton pump blocker for the treatment of acid-related disorders. Its potential to combat cytokine release syndrome (CRS) in patients with severely ill COVID-19 was investigated. Accordingly, it is recommended to use tocilizumabin combination with dexamethasone (or another corticosteroid at an equivalent dose) in certain hospitalized patients who are exhibiting rapid respiratory decompensation caused by COVID-19.
Target Activities